Ana Pena, PhD,  —

New research provides important insights into the process of activation and formation of cells that are crucial for fibrosis to occur, uncovering potential targets that can help control fibrosis in chronic diseases such as pulmonary fibrosis (PF). Scientists at the Lewis Katz School of Medicine at Temple University (LKSOM) discovered…

Final data from the PRAISE trial support the efficacy and safety of pamrevlumab, an investigational therapy for the treatment of idiopathic pulmonary fibrosis (IPF) being developed by FibroGen. Data showed that into-the-vein (intravenous) infusions of pamrevlumab reduced the decline in respiratory function by 60.3%. It also cut to…

Surgery is the most effective option to treat lung cancer in people with less severe idiopathic pulmonary fibrosis (IPF), a Korean study has found. For IPF patients who have a poorer prognosis (more advanced GAP stages), researchers recommend accounting for cancer clinical stage and estimated tolerability…

An exploratory Phase 2 study of Prometic‘s investigative oral therapy PBI-4050 in patients with idiopathic pulmonary fibrosis (IPF) showed “encouraging” results and no safety concerns, a study reports. Alone or in combination with Ofev (nintedanib), PBI-4050 was well-tolerated and showed…

As many as one in four people with idiopathic pulmonary fibrosis (IPF) may have the illness as a result of inhaling vapors, gas, dust, or fumes at work, according to an official statement by the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Such occupational…

An international group of experts and advocates in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs) have joined to create the Open Source Imaging Consortium (OSIC), a not-for-profit effort to advance the diagnosis of these illnesses with the help of digital imaging and machine learning. According…

Promedior‘s investigational therapy for idiopathic pulmonary fibrosis (IPF) — PRM-151 — continues to benefit patients after 76 weeks of treatment, slowing the decline in lung function and exercise capacity, while maintaining a similar safety profile as previous studies of PRM-151, an extension study shows. The results were…

Ofev (nintedanib) can prevent disease progression in people with idiopathic pulmonary fibrosis (IPF) regardless of their prognosis at treatment start as staged by the…

The New York State Department of Health has authorized the use of Veracyte‘s Envisia Genomic Classifier, the first commercially available test to help distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILD), without the need for risky surgery. Authorization takes effect immediately, making the Envisia…

The American Thoracic Society (ATS) Foundation and Boehringer Ingelheim have awarded a physician scientist at Northwestern University this year’s research grant in idiopathic pulmonary fibrosis (IPF). Paul Andrew Reyfman, MD, was the recipient of the $100,000 fellowship, which will help fund his project, “Single Cell Transcriptomic…